



PCT/AU2004/001438

Patent Office
Canberra

I, LEANNE MYNOTT, MANAGER EXAMINATION SUPPORT AND SALES hereby certify that annexed is a true copy of the Provisional specification in connection with Application No. 2003905882 for a patent by NOVAPHARM RESEARCH (AUSTRALIA) PTY LTD as filed on 24 October 2003.

WITNESS my hand this
Twenty-ninth day of October 2004

A handwritten signature in black ink, appearing to be 'LM' or similar, written over a horizontal line.

LEANNE MYNOTT
MANAGER EXAMINATION SUPPORT
AND SALES



AUSTRALIA

PATENTS ACT 1990

PROVISIONAL SPECIFICATION

FOR THE INVENTION ENTITLED:-

"DRIP TRAY TABLET"

The invention is described in the following statement:-

Field of the invention

This invention relates to a tablet for use in preventing biofilm growth in a drip
5 tray and drainage tube from said drip tray and to a method of manufacture thereof.
The invention extends to include use of the tablet for prevention of biofilm growth,
for example in a drip tray.

Background of the Invention

10

Drip trays are widely used in industrial and domestic environments where
water condenses. For example, in air conditioning systems and the like, it is usual to
provide a drip tray under condensation or refrigeration coils. Condensate falling from
the coils is collected in a drip tray which is provided with a drain connected to a water
15 waste system or recirculation system. Other situations in which a drip tray is used are
commonplace.

A problem with drip trays is that biofilm grows on wet surfaces in the tray.
Excessive biofilm growth can result in the drain becoming blocked which in turn can
20 cause the tray to overflow, and cause flooding.

It has been proposed to treat the water or tray surfaces with biocides to inhibit
such growth but such systems have been excessively costly in use. The biocides have
been non-oxidizing, and have been provided in tablet form. Since non-oxidising
25 biocides are not wide spectrum, i.e. are not effective against certain genera or strains
of biofilm-forming organisms, the efficacy of the biocides is reduced over a period of
time. Also the microorganisms present in the environment of the non-oxidising
biocide over an extended period gives rise to increasing resistance of the
microorganism to the biocide. Prior art treatments require the tray to be thoroughly
30 cleaned before use and to date no satisfactory answer to the problem in terms of
efficacy, biofilm remediation and bacterial resistance has been found. A further
difficulty in many cases relates to the trays not being removable and thus being unable
to be cleaned since the clearance between the bottom of the coils and the drip tray is
normally too limited to allow clear access.

In commercial air conditioning systems, drip trays are usually located in an air treatment plant of the building – an area with restricted access. Often the trays are positioned at a height of up to 5m, requiring use of a ladder, and their servicing is done by highly qualified technicians, i.e. expensive and time-consuming. It is not uncommon to find a tray that is serviced once every 12-24 months, if at all.

Any discussion of the prior art throughout the specification should in no way be considered as an admission that such prior art is widely known or forms part of common general knowledge in the field.

It is an object of preferred embodiments of the present invention to provide an improved method for controlling biofilm in a drip tray and its drainage line or the like, and to provide a tablet for use in the method, and a method of manufacture of such tablets.

Brief statement of the invention

The present inventors have conceived the idea of incorporating an enzyme in a drip tray tablet containing a biocide. This has been found not merely to kill microorganisms, but also to remove biofilm and prevent biofilm drain blockage.

According to one aspect the invention provides a tablet for use in a drip tray including a slowly soluble excipient, a biocide, at least one enzyme, and means for preserving enzyme activity in a moist environment.

By "slowly soluble" is meant an excipient such that the tablet will not fully dissolve in water at ambient temperature for a period of at least one month and preferably will not fully dissolve for more than 6 or even more preferably will not fully dissolve more than 12 months. An example of a suitable excipient may be selected from Poly Vinyl Alcohols (PVAs). Other excipients may be selected from high molecular weight polyethyleneglycols, high molecular weight polypropyleneglycols, esters or partial esters of said polyethyleneglycols or polypropyleneglycols, high molecular weight thermoplastic surfactants such as polyoxyethylenecondensates, polyoxypropylene

condensates, polyoxyethylenepolyoxypropylene copolymers with appropriate hydrophobes or blends of these and/or other appropriate compounds.

5 The enzyme may be one or a combination of enzymes and preferably is selected from proteolytic and/or other hydrolase enzymes.

10 Incorporating an enzyme into a drip tray tablet proved to be problematic in practice because in use the tablet in the drip tray becomes saturated with water. This destroys the enzyme activity in the non-dissolved part of the tablet in days or weeks, thus reducing the biofilm destroying properties of the enzymes.

15 According to a second aspect the invention provides a tablet according to the first aspect wherein the means for preserving the enzyme activity is inclusion in the tablet composition of a boron compound in a concentration sufficient to maintain the enzyme activity for at least three months during use.

20 A preferred means for preservation is borax, which the present inventor has found acts to preserve the enzyme activity in use for at least 3 months in the non-dissolved part of the tablet. The present invention thus provides matching between the enzyme activity and tablet dissolution parameters.

25 The invention may preferably contain excipient in an amount of from 2 to 95%, more preferably from 10 to 80%, even more preferably from 20 to 60% by weight of the tablet. The biocide may be preferably be present in an amount of from 0.1 to 20%, more preferably 0.5 to 10%, and most preferably from 1 to 5% by weight of the tablet. The enzyme may preferably be present in an amount of from 0.01 to 10%, more preferably 0.1 to 5% and most preferably 0.5 to 3% by weight of the tablet. The inhibitor is preferably present in an amount of from 0.1 to 10%, more preferably 0.2 to 5% and most preferably 1 to 3% by weight of the tablet.

30 According to a third aspect the invention provides a tablet for use in a drip tray according to the first or second aspect further including a surfactant.

For preference tablets according to the invention are made in a tablet press. Alternatively, the tablets may be made by extrusion and cutting, by pouring into moulds, or by providing in a slow release encapsulation.

5 Preferred embodiments of the invention

A preferred embodiment of the invention will now be described by way of example only.

10 Example 1

A tablet according to the invention is formulated as follows;

Chemical Name	Commercial Name	Cas No	Supplier	%w/w
C16-C18 Fatty Alcohol	Luhtensol AT50	102-60-3	Langdons	33
Polyethylene Glycol Ether (50EO)				
Polyvinyl alcohol	Gohsenol	G105	Nippon Gohsei	40
Sodium Sulfate		7757-82-6	APS Chem.	20
Calcium stearate			APS Chem	3
2 Bromo-2-Nitropropane-1,3 Diol	Bronopol/Canpres BNPD		Canpoint	2
Subtilisin-Protease Enzyme	Savinase 0.9T	52-51-7	Novozymes	2
Borax			Spectrum	1.5

15 The inclusion of a C16-C18 fatty alcohol or other surfactant is optional and depending on water quality may vary from 0.5 to 50% w/w. Different levels of saponification hydrolysis of PVA may be employed depending on the desired tablet solubility in cold or hot water. For the lowest solubility tablets higher degrees of saponification hydrolysis (e.g. Gohsenol N-500) should be used, while lower saponification hydrolysis of PVA (e.g. Gohsenol G105) will result in fast solubilising
20 in cold water.

The amount of sodium sulfate may be varied from about 5 to 70%w/w and acts as a densifier. The calcium stearate is an optional solubility modifier and mold release agent. Other biocides may be substituted for the 2-Bromo-2-Nitropropane-1,3-Diol and the concentration may be varied according to the biocide selected and conditions of use. Similarly other enzymes may be substituted for Savinase 0.9T.

Boric acid or other suitable compounds may be substituted for borax and at least 0.2%w/w will generally be needed.

A tablet according to the invention may be manufactured by the following procedure:

Example 2

20 -100 atm pressure is applied at ambient temperature to a powdered mixture having a composition according to Example 1. The mixture is pressed into a tablet mold, pre-treated with a releasing agent if required.

A suitable (accelerated) test method is as follows:

20

A tablet to be tested is placed into a 1L plastic tray filled with water. A thin jet of cold (20°C) tap water is introduced in the tray to allow full replacement of water every 10 minutes. The rate of dissolution of the tablet is observed and results are reported every 24 hours. Each 24-hr period of the above test corresponds roughly to 45 days under field conditions.

25

A tablet prepared in accordance with example 2 has a dissolution rate of 94 hours in the above test.

30

When Gohsenol N500 (low cold water solubility) is used instead of Gohsenol G105, the dissolution rate increases to 227 hours in the above test (equivalent to around 15 months in the field).

The rate of dissolution of the tablet is preferably maintained at between 4 and 10 days in the above test to correspond to 6-15 months in the field. While it is possible to extend the dissolution rate even further, to do so has been found to compromise biocidal and biofilm removal performance in some cases. Conditions in the field vary and biocide molecules may undergo some changes at extreme temperatures that may be encountered.

Comparison with prior art

A commercially available drip tray tablet which is composed of surfactants and biocide was inserted into a first metal drip tray with a flexible, transparent PVC tubing drain line that both had visible biofilm. The plant was situated in the locked plant room of an upper floor of a commercial building. The tablet was placed adjacent to the drain line. Over the ensuing six weeks the tablet not only did not remove the biofilm but the biofilm continued to develop to the extent that the drainage line from the drip tray became blocked. With the only available drainage from the tray closed off the water overflowed from the tray causing water damage to the floor below.

A second identical drip tray sited immediately adjacent to the first tray into which drained the condensate from an identically sized air conditioning cooling coil was at the same time fitted with a tablet with a composition matching that described in example 1. This tray and drain line also had visible biofilm at the time of tablet addition both adjacent to and in the drain line. When the drip trays were inspected after four weeks this drip tray was found to have no biofilm whatsoever in the immediate vicinity of the tablet and a lessened amount nearby. Most notably the biofilm in the drain line had visibly decrease almost to the point of complete removal.

The rate of dissolution of the tablet is largely dependant upon the temperature and humidity. At times of high temperature and humidity the tablet dissolves significantly faster due to the much greater amount of water dripping onto the tablet and may dissolve within four to eight weeks. At the other extreme, if temperatures and humidity are low, a tablet may not dissolve within twenty five to fifty weeks.

The rate of dissolution of the tablet can be largely controlled by varying the soluble high molecular weight components of the formulation, i.e. by increasing the molecular weight and the proportion of this slow dissolving component the tablet will last longer. Alternatively the size of the tablet can be increased. However the rate of
5 solution must be sufficiently high to ensure the efficacy of the enzyme and biocide combination contained in the tablet.

Formulations and methods of manufacture herein disclosed may be altered to an extent which will be apparent to those skilled in the art from the teaching hereof
10 without departing from the inventive concept herein disclosed.

DATED this 24th Day of October 2003
BALDWIN SHELSTON WATERS
Attorneys for: Novapharm Research (Australia) Pty Ltd
15

Document made available under the Patent Cooperation Treaty (PCT)

International application number: PCT/AU04/001438

International filing date: 20 October 2004 (20.10.2004)

Document type: Certified copy of priority document

Document details: Country/Office: AU
Number: 2003905882
Filing date: 24 October 2003 (24.10.2003)

Date of receipt at the International Bureau: 08 November 2004 (08.11.2004)

Remark: Priority document submitted or transmitted to the International Bureau in compliance with Rule 17.1(a) or (b)



World Intellectual Property Organization (WIPO) - Geneva, Switzerland
Organisation Mondiale de la Propriété Intellectuelle (OMPI) - Genève, Suisse